TOKYO (Reuters) - U.S. private equity firm Bain Capital said it may withdraw its tender offer proposal for Japanese IT firm ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

“Milacron is an iconic American manufacturing business with a 50-year legacy of driving innovation in plastics,” said Matt Evans, a partner at Bain Capital Special Situations in a statement.

Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Founded in 1678 ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Keith Largay joined Bain Capital’s real estate business as head of real estate capital markets, a spokesperson confirmed. It is a new position. Largay oversees the team’s debt and financing ...

Boston-based Bain Capital hired a JLL senior leader as its head of real estate capital markets. Keith Largay has taken the role at the investment firm, Bain announced in a LinkedIn post.

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about ¥510 ...

BAIN Capital is nearing a deal to buy Mitsubishi Chemical Group’s pharmaceutical unit, sources familiar with the matter said, adding to a dealmaking boom in Japan. The US-based private equity firm and ...